Adicet Bio develops gamma delta T cell therapies made from donor cells for autoimmune diseases and cancer. ACET reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | Wedbush | Maintained | Buy | |
| Sep 28 | HC Wainwright & Co. | Target raised | Buy | |
| Sep 18 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 6 | Guggenheim | Maintained | Buy |
Seasonality
How ACET has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in ACET in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACET is in one of them and how their past ACET trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACET in an article yet. Here's the latest on the wider market.
About Adicet Bio
Adicet Bio is a biotechnology company based in Boston, Massachusetts. It develops allogeneic gamma delta T cell therapies, made from donor cells so that they can be stored and given to patients on demand. Its lead candidate is being tested for autoimmune diseases such as lupus, and it is also developing a candidate for prostate cancer. The company's therapies are intended for patients with autoimmune diseases and cancer, and they are still in clinical trials.
- Headquarters
- Boston, MA